Navigation Links
Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Date:2/22/2010

LAIYANG, China, Feb. 22 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the second quarter of its fiscal year 2010 ended December 31, 2009.

    Second Quarter Highlights and Recent Events

    -- Revenue was $18.2 million, a decrease of 44.8% from the corresponding
       quarter ended December 31, 2008
    -- Gross profit was $13.5 million, compared to $25.8 million for the
       corresponding quarter ended December 31, 2008, and gross margin was
       74.3%, compared to 78.3% in the a year ago quarter ended December 31,
       2008
    -- Operating income was $7.1 million, down 37.4% from the corresponding
       quarter ended December 31, 2008
    -- Net income was $5.3 million, or $0.49 per basic share, compared $5.4
       million or $0.55 per basic share a year ago
    -- Excluding non-cash gains related to the change in fair value from
       derivative liabilities of $6.7 million and the amortization of debt
       discount and debt issuance costs related to convertible debentures of
       $5.8 million, non-GAAP adjusted net income was $4.4 million, or $0.29
       per fully diluted share for the three months ended December 31, 2009,
       compared to non-GAAP adjusted net income of $6.6 million,
'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine technology :

1. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
2. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... first quarter of 2011.  First quarter revenue increased to ... same period of 2010.  This increase was principally driven ... and license revenues.  Cambridge Research & Instrumentation, Inc. ("CRi"), ...
... 2011 Reportlinker.com announces that a new market ... Drug Delivery in Central Nervous System ... http://www.reportlinker.com/p0203542/Drug-Delivery-in-Central-Nervous-System-Diseases---technologiesmarkets-and-companies.html The delivery ... a challenge in the treatment of neurological disorders. ...
Cached Medicine Technology:Caliper Life Sciences Reports First Quarter 2011 Results 2Caliper Life Sciences Reports First Quarter 2011 Results 3Caliper Life Sciences Reports First Quarter 2011 Results 4Caliper Life Sciences Reports First Quarter 2011 Results 5Caliper Life Sciences Reports First Quarter 2011 Results 6Caliper Life Sciences Reports First Quarter 2011 Results 7Caliper Life Sciences Reports First Quarter 2011 Results 8Caliper Life Sciences Reports First Quarter 2011 Results 9Caliper Life Sciences Reports First Quarter 2011 Results 10Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2
... ... there are 6 key components of a successful strategic workforce planning process,” stated Jim ... components of strategic workforce planning and provides guidelines for implementing each of those 6 ... Waco, ...
... All Allied ... the health care industry. , ... (PRWEB) August 19, 2009 -- Today, All Allied Health Schools announced the launch of a new ... latest developments in the health care industry--and how these changes will affect health care careers ...
... Computed tomography (CT) scans are responsible for more than ... medical imaging exams. However, a newly adapted low-dose technique ... to reduce patient radiation resulting from CT up to ... September issue of the American Journal of Roentgenology ...
... led to fewer surgical deliveries, review shows , TUESDAY, ... increase the risk of Cesarean section delivery, according to ... Researchers reviewed available data on elective induction, in which ... it for medical reasons. Most of the studies included ...
... , , , ... Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced ... final approval from the U.S. Food and Drug Administration for ... Clonidine TDS is a generic version of Boehringer Ingelheim,s ...
... , CHICAGO, Aug. 18 Synch-Solutions is ... on Inc. magazine,s 2009 list of the 5,000 fastest ... Synch-Solutions, reflecting the company,s strong and steady advancement - even in ... and technology solutions for organizations across multiple industry sectors. "As an ...
Cached Medicine News:Health News:Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning 2Health News:All Allied Health Schools Launches "Health Care Community" 2Health News:All Allied Health Schools Launches "Health Care Community" 3Health News:Induced Labor May Prevent Need for Cesarean Section 2Health News:Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R) 2Health News:Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R) 3Health News:Synch-Solutions Named to Inc. Magazine's 2009 Ranking of the Fastest Growing Companies in the United States 2
The control unit circulates temperature-controlled water through disposable gel pads applied directly to the patient's body....
The Equator Convective Warmer incorporates LEVEL 1's unique, patented, temperature control technology to ensure delivery of the desired therapy to the patient....
The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results....
The Osom® Bvblue Test detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with Bacterial Vaginosis including Gardnerella, Bacteroides, Prevote...
Medicine Products: